Bob van de Water

Bob van de Water

Auto-generated profile, based on publicly available information

Bob van de Water

Leiden University, Leiden Academic Centre for Drug Research, Division of Cell Systems and Drug Safety, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Environment International
Verified
Journal Article
Open access
SBStephanie K Bopp
Stephanie K Bopp
RBRobert Barouki
Robert Barouki
WBWerner Brack
Werner Brack
SCSilvia Dalla Costa
Silvia Dalla Costa
JDJean Lou Dorne
Jean Lou Dorne
ÅBÅke Bergman
Åke Bergman
Humans and wildlife are exposed to an intractably large number of different combinations of chemicals via food, water, air, consumer products, and other media and sources. This raises concerns about their impact on public and environmental health. The risk assessment of chemicals for regulatory purposes mainly relies on the assessment of individual chemicals. If exposure to multiple chemicals is considered in a legislative framework, it is usually limited to chemicals falling within this framework and co-exposure to chemicals that are covered by a different regulatory framework is often neglected. Methodologies and guidance for assessing risks from combined exposure to multiple chemicals have been developed for different regulatory sectors, however, a harmonised, consistent approach for performing mixture risk assessments and management across different regulatory sectors is lacking. At the time of this publication, several EU research projects are running, funded by the current European Research and Innovation Programme Horizon 2020 or the Seventh Framework Programme. They aim at addressing knowledge gaps and developing methodologies to better assess chemical mixtures, by generating and making available internal and external exposure data, developing models for exposure assessment, developing tools for in silico and in vitro effect assessment to be applied in a tiered framework and for grouping of chemicals, as well as developing joint epidemiological-toxicological approaches for mixture risk assessment and for prioritising mixtures of concern. The projects EDC-MixRisk, EuroMix, EUToxRisk, HBM4EU and SOLUTIONS have started an exchange between the consortia, European Commission Services and EU Agencies, in order to identify where new methodologies have become available and where remaining gaps need to be further addressed. This paper maps how the different projects contribute to the data needs and assessment methodologies and identifies remaining challenges to be further addressed for the assessment of chemical mixtures.

6 March 2014 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
SRSreenivasa C. Ramaiahgari
Sreenivasa C. Ramaiahgari
MBMichiel W. Den Braver
Michiel W. Den Braver
BHBram Herpers
Bram Herpers
VTValeska Terpstra
Valeska Terpstra
JCJan N. M. Commandeur
Jan N. M. Commandeur
LPLeo S. Price
Leo S. Price

22 March 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MGMarjo de Graauw
Marjo de Graauw
MMMartine H. van Miltenburg
Martine H. van Miltenburg
Marjanka SchmidtMarjanka Schmidt
Marjanka Schmidt
CPChantal Pont
Chantal Pont
RLReshma Lalai
Reshma Lalai
BWBob van de Water
Bob van de Water
Annexin A1 (AnxA1) is a candidate regulator of the epithelial- to mesenchymal (EMT)-like phenotypic switch, a pivotal event in breast cancer progression. We show here that AnxA1 expression is associated with a highly invasive basal-like breast cancer subtype both in a panel of human breast cancer cell lines as in breast cancer patients and that AnxA1 is functionally related to breast cancer progression. AnxA1 knockdown in invasive basal-like breast cancer cells reduced the number of spontaneous lung metastasis, whereas additional expression of AnxA1 enhanced metastatic spread. AnxA1 promotes metastasis formation by enhancing TGFβ/Smad signaling and actin reorganization, which facilitates an EMT-like switch, thereby allowing efficient cell migration and invasion of metastatic breast cancer cells.

19 May 2011 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
YZYinghui Zhang
Yinghui Zhang
MMMarja Moerkens
Marja Moerkens
SRSreenivasa Ramaiahgari
Sreenivasa Ramaiahgari
HBHans de Bont
Hans de Bont
LPLeo Price
Leo Price
BWBob van de Water
Bob van de Water
Insulin-like growth factor 1 (IGF-1) receptor (IGF-1R) is phosphorylated in all breast cancer subtypes. Past findings have shown that IGF-1R mediates antiestrogen resistance through cross-talk with estrogen receptor (ER) signaling and via its action upstream of the epidermal growth factor receptor and human epidermal growth factor receptor 2. Yet, the direct role of IGF-1R signaling itself in antiestrogen resistance remains obscure. In the present study, we sought to elucidate whether antiestrogen resistance is induced directly by IGF-1R signaling in response to its ligand IGF-1 stimulation.

1 February 2020 in iScience
Verified
Journal Article
Open access
HYHuan Yang
Huan Yang
MNMarije Niemeijer
Marije Niemeijer
BWBob van de Water
Bob van de Water
JBJoost Beltman
Joost Beltman
The unfolded protein response (UPR) pathway senses unfolded proteins and regulates proteostasis and cell fate through activity of the transcription factors ATF4, ATF6, and XBP1 within a complex network of three main branches. Here, we investigated contributions of the three branches to UPR activity in single cells using microscopy-based quantification and dynamic modeling. BAC-GFP HepG2 reporter cell lines were exposed to tunicamycin, and activation of various UPR components was monitored for 24 h. We constructed a dynamic model to describe the adaptive UPR signaling network, for which incorporation of all three branches was required to match the data. Our calibrated model suggested that ATF6 shapes the early dynamics of pro-apoptotic CHOP. We confirmed this hypothesis by measurements beyond 24 h, by perturbing single siRNA knockdowns and by ATF6 measurements. Overall, our work indicates that ATF6 is an important regulator of CHOP, which in turn regulates cell fate decisions.

16 March 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
WRWies van Roosmalen
Wies van Roosmalen
SDSylvia Emmanuelle Le Dévédec
Sylvia Emmanuelle Le Dévédec
OGOfra Golani
Ofra Golani
MSMarcel Smid
Marcel Smid
IPIrina Pulyakhina
Irina Pulyakhina
BWBob van de Water
Bob van de Water
Tumor cell migration is a key process for cancer cell dissemination and metastasis that is controlled by signal-mediated cytoskeletal and cell matrix adhesion remodeling. Using a phagokinetic track assay with migratory H1299 cells, we performed an siRNA screen of almost 1,500 genes encoding kinases/phosphatases and adhesome- and migration-related proteins to identify genes that affect tumor cell migration speed and persistence. Thirty candidate genes that altered cell migration were validated in live tumor cell migration assays. Eight were associated with metastasis-free survival in breast cancer patients, with integrin β3–binding protein (ITGB3BP), MAP3K8, NIMA-related kinase (NEK2), and SHC-transforming protein 1 (SHC1) being the most predictive. Examination of genes that modulate migration indicated that SRPK1, encoding the splicing factor kinase SRSF protein kinase 1, is relevant to breast cancer outcomes, as it was highly expressed in basal breast cancer. Furthermore, high SRPK1 expression correlated with poor breast cancer disease outcome and preferential metastasis to the lungs and brain. In 2 independent murine models of breast tumor metastasis, stable shRNA-based SRPK1 knockdown suppressed metastasis to distant organs, including lung, liver, and spleen, and inhibited focal adhesion reorganization. Our study provides comprehensive information on the molecular determinants of tumor cell migration and suggests that SRPK1 has potential as a drug target for limiting breast cancer metastasis.